California's $750 Million Various-Purpose GO Bonds Rated 'A' On Large, Diverse Economy Nov 09

  • ID: 2048982
  • November 2009
  • Region: California
  • Standard & Poors
1 of 3

SAN FRANCISCO (Standard & Poor's) Nov. 2, 2009--Standard & Poor's Ratings Services assigned its 'A' long-term rating to the State of California's approximately $750 million various-purpose general obligation (GO) bonds (federally taxable Build America Bonds (BAB)). At the same time, Standard & Poor's affirmed its 'A' long-term and underlying ratings (SPUR) on the state's $58.53 billion of existing GO debt. In addition, we affirmed our 'A-1' rating on the state's GO commercial paper. Finally, Standard & Poor's affirmed its 'SP-1' short-term rating on the state's $8.8 billion revenue anticipation notes (RAN). "The 'A' long-term rating and SPUR generally reflect our view of the state's exceptionally large and diverse economy, with a state GDP equivalent to 12.8% of U.S. GDP; economy...

Companies mentioned in this report are:
- California

Action: Affirmed
Action: New Rating
Action: Outlook: Negative

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- California

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.